VIR-2218
VIR-2218-V107
Phase 1 small_molecule active
Quick answer
VIR-2218 for Hepatic Impairment is a Phase 1 program (small_molecule) at Vir Biotechnology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vir Biotechnology
- Indication
- Hepatic Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active